GP IIb/IIIa inhibitors in coronary artery disease management: What the latest trials tell us
Cleveland Clinic Journal of Medicine. 2001 December;68(12):1017-1023
December 1, 2001|Cleveland Clinic Journal of Medicine
Author and Disclosure Information
ABSTRACTRecent clinical trials have refined our understanding of how the glycoprotein (GP) IIb/IIIa inhibitors should best be used. These trials examined whether there are clinical differences between agents, whether empiric use of GP IIb/IIIa inhibitors in acute coronary syndromes is justified, and whether these drugs might allow for early invasive management in acute coronary syndromes.
